BNP Paribas Financial Markets Trims Holdings in LivaNova PLC (NASDAQ:LIVN)

BNP Paribas Financial Markets cut its holdings in LivaNova PLC (NASDAQ:LIVN) by 63.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,845 shares of the company’s stock after selling 48,570 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.05% of LivaNova worth $1,463,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Fifth Third Bancorp lifted its stake in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares during the period. Canada Pension Plan Investment Board bought a new position in LivaNova during the 2nd quarter valued at about $88,000. Central Pacific Bank Trust Division bought a new position in LivaNova during the 3rd quarter valued at about $178,000. TradeLink Capital LLC bought a new position in LivaNova during the 2nd quarter valued at about $208,000. Finally, GSA Capital Partners LLP bought a new position in LivaNova during the 3rd quarter valued at about $292,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Price Performance

NASDAQ LIVN opened at $49.71 on Monday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 12 month low of $43.15 and a 12 month high of $64.47. The company’s 50 day moving average is $52.19 and its two-hundred day moving average is $51.74. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of 118.36 and a beta of 0.98.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Monday, November 25th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Finally, Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LivaNova presently has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.